Background:
An ophthalmic artery occlusion (OAO) is a partial or complete obstruction of the ophthalmic artery and may lead to severe ischemia of the affected globe and associated ocular tissues. There is central retinal artery occlusion (CRAO) that cause partial or complete obstruction of the central retinal artery; branch retinal artery occlusion (BRAO) that is a partial or complete obstruction of any of the branch tributaries of the central retinal artery; and artertic retinal arterial occlusion (RAO) caused by giant cell arteritis. The recommendations of this Preferred Practice Pattern (PPP) are based on Cochrane-identified reliable systematic reviews. An OAO, CRAO or BRAO can be associated with life-threatening conditions and their incidence increases with age. Risk factors to highlight include cigarette smoking, hypertension, high serum lipid levels, coagulopathy, body mass index, diabetes, and cardiac disease, including atrial fibrillation are all important modifiable risk factors associated with retinal emboli.
Rationale for treatment:
A careful systemic evaluation for any underlying disorder(s) should guide therapy. Specifically, causes of vasculitis that represent an ophthalmologic emergency. Acute, symptomatic OAO, CRAO, and BRAO represent urgent ophthalmic conditions and require prompt evaluation. Due to the high risk of ischemic stroke in cases if ocular arterial occlusions, a prompt referral to a stroke center for a medical evaluation is recommended.
Care Process: Patient outcome criteria are to improve or stabilize visual function, reduce the risk of severe consequences (e.g., further vision loss, neovascular glaucoma) or cerebral and myocardial infarction, encourage smoking cessation, controlling chronic systematic diseases (e.g., diabetes, hypertension), brining awareness of the patient's retinal disease to their primary care physician, and maintain or improve quality of life. Thus, an initial examination of a patient starts with a careful medical history, which includes any known systemic disease.
Management recommendations are detailed in this PPP, which includes surgical management and follow-up evaluation. Since diabetes is a common contributor to RAO, the ophthalmologist may wish to become familiar with the Diabetic Retinopathy PPP.
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As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that identify characteristics and components of quality eye care. Appendix 1 describes the core criteria of quality eye care.
The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.
These documents provide guidance for the pattern of practice, not for the care of a particular individual. While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice.
Preferred Practice Pattern® guidelines are not medical standards to be adhered to in all individual situations. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein.
References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved U.S. Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
Innovation in medicine is essential to ensure the future health of the American public, and the Academy encourages the development of new diagnostic and therapeutic methods that will improve eye care. It is essential to recognize that true medical excellence is achieved only when the patients' needs are the foremost consideration.
All Preferred Practice Pattern® guidelines are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all PPPs are current, each is valid for 5 years from the approved by date unless superseded by a revision. Preferred Practice Pattern guidelines are funded by the Academy without commercial support. Authors and reviewers of PPPs are volunteers and do not receive any financial compensation for their contributions to the documents. The PPPs are externally reviewed by experts and stakeholders, including consumer representatives, before publication. Preferred Practice Pattern® guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network 1 (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation 2 (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Policy, and the American College of Physicians. 3 ◆ All studies used to form a recommendation for care are graded for strength of evidence individually, and that grade is listed with the study citation.
◆ To rate individual studies, a scale based on SIGN 1 is used. The definitions and levels of evidence to rate individual studies are as follows:
I++
High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias I+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias I-Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias II++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal II+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal II-Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal III Nonanalytic studies (e.g., case reports, case series) ◆ Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE 2 as follows: All recommendations for care in this PPP were rated using the system described above. Ratings are embedded throughout the PPP main text in italics. Acute, symptomatic OAO, CRAO, or BRAO from embolic etiologies should prompt an immediate referral to the nearest stroke referral center for prompt assessment for consideration of an acute intervention. The precise timing of evaluation for patients with an asymptomatic but newly diagnosed CRAO or BRAO is unclear, though these patients still warrant a timely referral.
In general, there are no proven treatments to reverse the vision loss caused by CRAO, BRAO, or OAO.
In vascular occlusive disorders of the eye, there is an increased risk for posterior and/or anterior segment neovascularization. Patients with greater ischemia require closer and more frequent follow-up. Panretinal photocoagulation (PRP) treatment is recommended for patients who develop iris or retinal neovascularization.
The arterial circulation to the eye involves many branches. Any one of these branches may have impaired flow that results from an obstruction. An embolus, defined as "a solid, liquid or gaseous mass carried by the blood to a site distant from its origin," can occlude the vessel or lead to thrombus formation (i.e., a blood clot). Inflammation of a retinal vessel wall, or vasculitis, may also lead to an occlusion or thrombus formation. In general, an obstruction of either an ophthalmic or retinal arteriole requires a careful evaluation for systemic diseases. Numerous studies have reported an association between symptomatic retinal artery occlusion (RAO) and stroke. [4] [5] [6] [7] [8] [9] [10] [11] [12] An ophthalmic artery occlusion (OAO) is a partial or complete obstruction of the ophthalmic artery A CRAO is a rare condition that has an incidence of approximately 1 per 100,000 in a U.S. population 14 or 7 to 10 per 100,000 in an entire Korean population over age 65. 15 The incidence likely increases with age, 14, 15 and the mean age at presentation in the United States is the early 60s. 14 CRAOs have also rarely been documented in children. 16 A CRAO commonly leads to retinal ischemia and subsequent retinal cell death.
Patients presenting with a CRAO typically describe a sudden, painless decrease in the visual acuity and field of vision in one eye that occurs over a period of seconds. 14 In 1% to 2% of cases, there is a bilateral occurrence. 17 The presenting visual acuity may vary widely, and the patient may or may not have readily visible fundus abnormalities. A deep retinal whitening (i.e., from paracentral acute middle maculopathy [PAMM] with an inner nuclear layer of hyper-reflectivity may be noted initially before progression to a more complete CRAO. 18 The classic appearance of retinal whitening and a cherry red spot may be absent or very subtle in the early stages, depending largely on the timing of the examination relative to the onset of obstruction. However, within several hours, the classic appearance of retinal whitening with the associated cherry red spot on the foveal center is typical.
Retinal whitening is caused by opacification of the swollen, ischemic parafoveal nerve fiber layers.
The cherry red spot is seen because the foveal center, free of nerve fiber layers, transmits the normal coloration of the underlying, unaffected choroid. Hence, the normally perfused tissues appear red against the ischemic background of the nerve fiber layer.
Another key finding is the slow segmental blood flow, referred to as boxcar segmentation, that is observed within the retinal arterioles and veins. Boxcar segmentation of blood in the retinal veins and arteries is best visualized by means of slit-lamp biomicroscopy of the posterior. Approximately 15% to 25% of eyes will have a cilioretinal artery that perfuses a portion of the macula and, thus, spares a portion of the central vision. 19, 20 In a CRAO, there are typically no intraretinal hemorrhages, and the veins will have a normal caliber. This is in contrast to retinal vein occlusion, which is typified by diffuse intraretinal hemorrhages and venous tortuosity and dilation.
In cases of CRAO, the presenting visual acuity in a patient with an acute CRAO tends to be in the range of 20/200 to counting-fingers, yet can be as good as 20/20, depending on the presence of a cilioretinal artery and the degree of obstruction within the artery. In contrast, the presenting visual acuity for an OAO is usually hand motions or worse. This poor visual acuity is due to the location of the obstruction, which is proximal to the branch point of the ciliary arteries that provide flow to the choroid and portions of the optic nerve. Ophthalmic retinal artery occlusions and CRAOs will have a relative afferent pupillary defect that is commensurate with the degree of ischemia.
Over time, an occluded artery will eventually open and begin to reperfuse the retina. However, the visual acuity usually remains poor. 20 In vivo measurements of macular and nerve fiber layer thickness in RAO demonstrate that the inner retina thickens acutely, then subsequently thins from ischemiarelated atrophy, and the retinal vessels usually remain attenuated in a process that appears to evolve over months. 21 In some cases, there is a progression from PAMM to more complete inner retinal hyper-reflectivity. 18, 22 Iris neovascularization may develop in about 20% of cases of CRAO, and as soon as one week, but typically within 30-60 days, following a CRAO. The incidence or neovascularization, and the rapidity of its onset, is likely related to the level of overall ocular and retinal ischemia. 23 Cilioretinal more easily impeded as a result of higher outflow resistance. Also, the ciliary circulation lacks the autoregulatory mechanism of the retinal circulation that compensates for changes in the intravascular pressure. Instead, the choroidal circulation is largely regulated by sympathetic innervation. 24 The combination of a CRAO or BRAO with a CRVO is rare; it usually is an indicator of an active systemic disease or it may occur in the setting of a retrobulbar hemorrhage. 25 Other etiologies include autoimmune disorders, 26 malignancies, blood dyscrasias, leukemia, and superior thoracic inlet lesions. 27 Patients with this combination of obstructions will generally have both dilated and tortuous veins, along with intraretinal hemorrhages in conjunction with broad areas of retinal ischemia, infarction, poor visual function, a poor prognosis, and a high risk (80%) of neovascular glaucoma. 25 Platelet-fibrin-cholesterol emboli (Hollenhorst plaques) are common emboli responsible for RAOs. The incidence of RAOs increases with age. 15 The incidence patterns for CRAO and stroke are similar;
incidence increases with age (peaking near age 80) and occurs more frequently in men. 29 Similarly, the incidence reported from Korea was 7 to10
cases per 100,000 among individuals aged 65 to 89 years, increasing with age. 15 Branch retinal artery occlusions are also uncommon. In an Australian study of 3654 subjects over 49 years of age screened by means of a detailed eye examination, asymptomatic retinal emboli were present in about 1.4% of the population (95% confidence interval [CI] = 1.0-1.8), increasing with age. 30 In the 10-year follow-up of this cohort from the Blue Mountains Eye Study, the incidence of retinal emboli increased to a 3% risk in the 1952 10-year survivors. 31 Age was the key risk factor and there was not a significant gender predilection.
Cigarette smoking, hypertension, body mass index, high serum lipid levels, diabetes, coagulopathy and cardiac disease, including atrial fibrillation are all important modifiable risk factors associated with retinal emboli. 6, 325, 9, [33] [34] [35] Central RAOs are commonly due to vascular embolic obstruction. One study reviewed a large number of ocular vascular occlusive cases and described varying degrees of recovery resulting from the inclusion of treatment for cases of giant cell arteritis. 36 The reported recovery rate is in contrast to the rate of less than 10% for nonarteritic CRAO patients who experienced any meaningful recovery of vision. 37 A careful systemic evaluation for any underlying disorder(s) should guide therapy. Specifically, causes of vasculitis, such as GCA, represent an ophthalmologic emergency. GCA typically affects Caucasians over 50 years of age with clinical findings of optic disc swelling, CRAO, and absence of emboli. Often, there is history of temporal tenderness, jaw claudication, weight loss, proximal myalgia, or fever. C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) are typically elevated. In cases of GCA, prompt initiation of systemic corticosteroid therapy is critical to prevent vision loss in the fellow eye or vascular occlusion elsewhere. 38, 39 Acute, symptomatic OAO, CRAO, and BRAO represent urgent ophthalmic conditions and require prompt evaluation. Such occlusions may represent an important clinical indicator of an embolic, inflammatory, infectious, or other process that may require a systemic medical evaluation that is both urgent and targeted to the patient's presentation and medical history. In most cases of CRAO, a prompt referral to a stroke center for a medical evaluation is recommended because the risk of ischemic stroke is high during the first 1 to 4 weeks, ranging from 3 -6% in two studies. 28, 35 The incidence of concurrent stroke has been found to be 20-24% in two retrospective studies. 11, 40 One of these studies identified via diffusion weighted magnetic resonance imaging, but not brain computed tomography, acute cortical lesions in subjects imaged within 7 days of ocular presentation. 41 Thus, a recommendation for urgent workup is warranted. 42 The rationale for acute management of an RAO is very limited. Current evidence for effective interventional treatment for the ocular condition, other than corticosteroids for GCA, is controversial and limited to level II data. Thrombolytic or interventional treatments that attempted to preserve or recover vision in CRAO or BRAO have never been proven to be effective. [43] [44] [45] The use of hyperbaric oxygen therapy (100% oxygen over 9 hours) has demonstrated efficacy over observation alone in several small randomized trials. 46 At present, only one-third of ophthalmologists transfer patients with incident CRAO to an emergency department for immediate evaluation. 28 Growing evidence recommends that acute RAO (symptoms within 24 hours) be treated as a medical emergency and be referred immediately to an emergency department or stroke center facility for neurological evaluation because of the increased risk of central nervous system stroke. 28, 35 Up to 24% of these patients have concurrent cerebrovascular accident on diffusion weighted MRI. 11, 40, 42 Additionally, a new significant systemic cardiovascular condition (typically clinically significant carotid stenosis) is discovered in up to 70% of patients with symptomatic CRAO. 6 A patient with symptomatic RAO should be referred for an urgent evaluation within 1 week's onset because the risk of stroke is highest within the first 7 days and remains elevated for 30 days. 42, 47 Silent brain infarction is a frequent finding in unselected patients with acute BRAO/CRAO or amaurosis fugax, and these silent infarctions bear a high risk for future stroke. These patients should undergo prompt referral to a stroke center. 47 Panretinal photocoagulation (PRP) with or without anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended for patients who develop iris or retinal neovascularization. 48 Although PRP will not improve the visual acuity or field of vision, it will likely decrease VEGF production and subsequent progression to iris neovascularization and neovascular glaucoma. In acute cases, the provider may elect to initiate treatment with an intravitreal anti-VEGF agent (off-label indication) to supplement or to help facilitate PRP treatment. 49 Patient outcome criteria include the following: systemic disease(s) and, second, to determine specifically whether the patient is at risk for a subsequent stroke or myocardial infarction. An emergency department is the next option for an urgent evaluation, with clear instructions that the patient has experienced an eye "stroke." An expedited workup offers the best opportunity to evaluate, assess, and manage the risk for cerebral stroke or myocardial infarction. A central nervous system infarction is defined as brain, spinal cord, or retinal cell death attributable to ischemia, based on neuropathological neuroimaging and/or clinical evidence of permanent injury. 54 At present, there is no conclusive evidence to support referring asymptomatic patients who have a BRAO for an expedited stroke workup.
Experts appointed by the American Heart Association suggest that for patients presenting with symptomatic RAO a critical initial systemic evaluation be performed at the nearest acute stroke-ready hospital or stroke center. 34 In general, older individuals presenting with an RAO should also be evaluated for atheromatous and embolic vascular etiologies. Patients 50 years or older should undergo a workup for embolic sources. 55 In the absence of a clear etiology such as an embolus, the workup should include an evaluation for antiphospholipid antibodies and other hematologic diatheses, and autoimmune or other hypercoagulable states. 5 For example, Susac syndrome should be considered in younger patients presenting with multiple or recurrent BRAOs. 56 This syndrome has a triad of hearing loss (usually low frequency), central nervous system lesions (especially of the corpus callosum), and
BRAOs. The clinician should also inquire about the signs or symptoms of vascular compromise associated with a carotid dissection (e.g., neck or face pain following recent trauma).
Poor choroidal circulation on fluorescein angiography or Indocyanine Green Angiography is suggestive of OAO. A major ophthalmic arterial obstruction may represent the initial manifestation of a systemic or embolic process that may subsequently involve the central nervous system or other organ systems. 9, 57 Stroke risk associated with newly diagnosed OAO, CRAO, or BRAO may be as high as 25%. 4, 11, 35, 47 An initial history for retinal and ophthalmic artery occlusion should consider the following elements: The initial examination should include the following elements: Although fluorescein angiography remains a valuable tool for physicians who diagnose and treat patients with retinal vascular disease, there are potential risks associated with the procedure. Severe medical complications may occur, including death, which has been reported in approximately 1 per 200,000 patients. 59 Fluorescein dye crosses the placenta into the fetal circulation, 60 yet detrimental effects of fluorescein dye on a fetus have not been documented.
Ultrasonography may be helpful to assess the anatomic status of the retina in the presence of a significant vitreous hemorrhage or other media opacity.
Acute, symptomatic, posterior segment arterial occlusions represent an emergent ophthalmic condition 61 and require prompt evaluation. They may be partial or complete, depending on whether there is evidence of blood flow. 62 These vascular occlusions may represent an important clinical indicator of a more severe systemic disorder or of an embolic, inflammatory, infectious, or other process that may require a systemic medical evaluation that is both urgent and targeted to the patient as well as to his or her presentation and medical history. Immediate referral to a stroke center for a medical evaluation is advised. If a stroke center is not available, an emergency room is the next option.
In general, there are no proven therapies or treatments for symptomatic artery occlusions. There are case reports, small case series, and uncontrolled studies that suggest that several potential interventions may be helpful. However, there are no level I data to support any single specific therapy.
Initial treatment of an acute CRAO may include digital massage, anterior chamber paracentesis, vasodilation, breathing into a paper bag, carbogen therapy, topical pressure-lowering therapies, or hyperbaric chambers. The rates of silent cerebral ischemia in RAO is the same as in hemispheric TIA, and the recommendation from multiple clinical trials is that TIA be worked up as stroke in the acute phase. Given the expected similarity of pathogenesis, RAO patients should be considered in the same way. 42 None of these interventions has demonstrated significant benefit when compared to with the natural history of the disorder. In fact, recent metanalysis suggests that eyes receiving conservative therapy do worse than controls. 63 More aggressive treatments, such as thrombolysis or transluminal neodymium yttrium-aluminum-garnet (Nd:YAG) laser embolysis, have associated risks and cannot be currently recommended in the absence of strong evidence-based data. [64] [65] [66] Both intra-arterial and intravenous thrombolytics have been investigated. 67, 68 However, there remains strong controversy about the best management strategy. There are meaningful limitations to establishing a reliable study design for such trials, especially given the complexity in disease variables and timing for intervention. Also, the low incidence of symptomatic arterial occlusions, especially within optimal time constraints, limits enrollment of patients for interventional studies. The need for systemic testing and prompt intervention creates urgency and severely limits the study design. 64 At this point, there is insufficient evidence to support intra-arterial antifibrinolytic therapy for CRAO. 45 Physicians who manage a cilioretinal artery occlusion should first consider GCA in patients over 50 years of age. Alternatively, if there is an embolus involved with the cilioretinal circulation, a systemic evaluation similar to that for a CRAO should be initiated.
The patient with concomitant retinal artery and vein occlusions should be followed for the development of anterior segment neovascularization. 48 When ocular neovascularization is present, prompt PRP is indicated. The off-label use of intravitreal anti-VEGF agents may be helpful to optimize visualization when hyphemia or vitreous hemorrhage are present limiting visibility for PRP, and to minimize treatment-related complications such as macular edema that may follow complete PRP. Off-label anti-VEGF injections may help facilitate the laser application. When a vitreous hemorrhage is present that limits the view for laser application, temporizing anti-VEGF injections may be considered before pars plana vitrectomy.
As with a CRAO, multiple treatments for BRAO have been proposed; however, there are currently insufficient data to demonstrate any conclusive benefits from intervention beyond the natural history of the disease. 69 When presented with an asymptomatic BRAO, the most important approach for the clinician is to conduct a systemic evaluation that includes a careful medical history and an assessment for systemic disease, preferably in conjunction with the patient's internist.
For symptomatic carotid disease with more than a 70% carotid artery occlusion, an endarterectomy has demonstrated a better outcome than medical therapy. 5, [70] [71] [72] When the carotid occlusion is between 50% and 70%, the value of endarterectomy is less certain. 5, 73 The role of imaging for active carotid disease and subsequent therapy is currently evolving.
In general, antiplatelet and statin therapies will apply to the vast majority of affected patients. Carotid surgery will apply to less than 30% of patients. 11, 47, 73 Panretinal photocoagulation is occasionally required in RAO and may be postponed until neovascularization is detected. However, in the presence of anterior segment neovascularization, and especially when neovascular glaucoma occurs, prompt laser PRP or anti-VEGF therapy with prompt or delayed PRP should be performed.
The follow-up evaluation includes a history and examination.
A follow-up history should include changes in the following: Examination results should be communicated promptly to the physician(s) managing the patient. An
Eye MD Examination Report Form is available from the American Academy of Ophthalmology. 80 Because many of the recommendations are based on limited data, additional research on treatment of acute ischemic stroke 34 and RAO is needed.
Many patients with RAO or OAO will lose substantial vision despite various treatment options.
Patients who fail to respond and those for whom further treatment is unavailable should be provided with proper professional support and considered for referrals for counseling, vision rehabilitation, or social services as appropriate. 81 Patients with functionally limiting postoperative visual impairment should be considered for referral for vision rehabilitation and social services. 81, 82 More information on vision rehabilitation, including materials for patients, is available at www.aao.org/low-vision-andvision-rehab.
Providing quality care is the physician's foremost ethical obligation, and is the basis of public trust in physicians.
AMA Board of Trustees, 1986
Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.
The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes the science and art of medicine to help alleviate patient fear and suffering. The ophthalmologist strives to develop and maintain clinical skills at the highest feasible level, consistent with the needs of patients, through training and continuing education. The ophthalmologist evaluates those skills and medical knowledge in relation to the needs of the patient and responds accordingly. The ophthalmologist also ensures that needy patients receive necessary care directly or through referral to appropriate persons and facilities that will provide such care, and he or she supports activities that promote health and prevent disease and disability.
The ophthalmologist recognizes that disease places patients in a disadvantaged, dependent state. The ophthalmologist respects the dignity and integrity of his or her patients, and does not exploit their vulnerability.
Quality ophthalmic care has the following optimal attributes, among others.
◆ The essence of quality care is a meaningful partnership relationship between patient and physician. The ophthalmologist strives to communicate effectively with his or her patients, listening carefully to their needs and concerns. In turn, the ophthalmologist educates his or her patients about the nature and prognosis of their condition and about proper and appropriate therapeutic modalities. This is to ensure their meaningful participation (appropriate to their unique physical, intellectual and emotional state) in decisions affecting their management and care, to improve their motivation and compliance with the agreed plan of treatment, and to help alleviate their fears and concerns.
◆ The ophthalmologist uses his or her best judgment in choosing and timing appropriate diagnostic and therapeutic modalities as well as the frequency of evaluation and follow-up, with due regard to the urgency and nature of the patient's condition and unique needs and desires. ◆ The ophthalmologist carries out only those procedures for which he or she is adequately trained, experienced and competent, or, when necessary, is assisted by someone who is, depending on the urgency of the problem and availability and accessibility of alternative providers. ◆ Patients are assured access to, and continuity of, needed and appropriate ophthalmic care, which can be described as follows.
◆
The ophthalmologist treats patients with due regard to timeliness, appropriateness, and his or her own ability to provide such care.
The operating ophthalmologist makes adequate provision for appropriate pre-and postoperative patient care.
◆ When the ophthalmologist is unavailable for his or her patient, he or she provides appropriate alternate ophthalmic care, with adequate mechanisms for informing patients of the existence of such care and procedures for obtaining it.
The ophthalmologist refers patients to other ophthalmologists and eye care providers based on the timeliness and appropriateness of such referral, the patient's needs, the competence and qualifications of the person to whom the referral is made, and access and availability.
The ophthalmologist seeks appropriate consultation with due regard to the nature of the ocular or other medical or surgical problem. Consultants are suggested for their skill, competence, and accessibility.
They receive as complete and accurate an accounting of the problem as necessary to provide efficient and effective advice or intervention, and in turn respond in an adequate and timely manner.
The ophthalmologist maintains complete and accurate medical records.
On appropriate request, the ophthalmologist provides a full and accurate rendering of the patient's records in his or her possession.
The ophthalmologist reviews the results of consultations and laboratory tests in a timely and effective manner and takes appropriate actions.
The ophthalmologist and those who assist in providing care identify themselves and their profession.
For patients whose conditions fail to respond to treatment and for whom further treatment is unavailable, the ophthalmologist provides proper professional support, counseling, rehabilitative and social services, and referral as appropriate and accessible. ◆ Prior to therapeutic or invasive diagnostic procedures, the ophthalmologist becomes appropriately conversant with the patient's condition by collecting pertinent historical information and performing relevant preoperative examinations. Additionally, he or she enables the patient to reach a fully informed decision by providing an accurate and truthful explanation of the diagnosis; the nature, purpose, risks, benefits, and probability of success of the proposed treatment and of alternative treatment; and the risks and benefits of no treatment. ◆ The ophthalmologist adopts new technology (e.g., drugs, devices, surgical techniques) in judicious fashion, appropriate to the cost and potential benefit relative to existing alternatives and to its demonstrated safety and efficacy.
◆ The ophthalmologist enhances the quality of care he or she provides by periodically reviewing and assessing his or her personal performance in relation to established standards, and by revising or altering his or her practices and techniques appropriately. ◆ The ophthalmologist improves ophthalmic care by communicating to colleagues, through appropriate professional channels, knowledge gained through clinical research and practice. This includes alerting colleagues of instances of unusual or unexpected rates of complications and problems related to new drugs, devices or procedures. ◆ The ophthalmologist provides care in suitably staffed and equipped facilities adequate to deal with potential ocular and systemic complications requiring immediate attention.
◆ The ophthalmologist also provides ophthalmic care in a manner that is cost effective without unacceptably compromising accepted standards of quality. 
